R
40.80
0.42 (1.04%)
| Previous Close | 40.38 |
| Open | 40.40 |
| Volume | 712,892 |
| Avg. Volume (3M) | 1,598,185 |
| Market Cap | 7,599,489,536 |
| Price / Sales | 9.04 |
| Price / Book | 3.31 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2025 - 12 May 2025 |
| Diluted EPS (TTM) | -3.58 |
| Total Debt/Equity (MRQ) | 6.00% |
| Current Ratio (MRQ) | 14.20 |
| Operating Cash Flow (TTM) | -557.44 M |
| Levered Free Cash Flow (TTM) | -347.69 M |
| Return on Assets (TTM) | -18.66% |
| Return on Equity (TTM) | -29.33% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Revolution Medicines, Inc. | Bearish | Bullish |
AIStockmoo Score
1.1
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.13 |
|
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 2.00% |
| % Held by Institutions | 106.89% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Janus Henderson Group Plc | 31 Dec 2024 | 9,483,999 |
| Baker Bros. Advisors Lp | 31 Dec 2024 | 7,936,972 |
| Nextech Invest Ltd. | 31 Dec 2024 | 7,601,087 |
| Paradigm Biocapital Advisors Lp | 31 Dec 2024 | 6,553,111 |
| Boxer Capital, Llc | 30 Sep 2024 | 4,279,464 |
| Boxer Capital Management, Llc | 31 Dec 2024 | 4,279,464 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 73.00 (HC Wainwright & Co., 78.92%) | Buy |
| Median | 65.50 (60.54%) | |
| Low | 59.00 (Needham, 44.61%) | Buy |
| Average | 65.75 (61.15%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 36.14 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wedbush | 28 Apr 2025 | 67.00 (64.22%) | Buy | 41.47 |
| Needham | 08 Apr 2025 | 59.00 (44.61%) | Buy | 31.13 |
| 27 Feb 2025 | 59.00 (44.61%) | Buy | 39.08 | |
| Stifel | 01 Apr 2025 | 64.00 (56.86%) | Buy | 33.62 |
| 27 Feb 2025 | 78.00 (91.18%) | Buy | 39.08 | |
| HC Wainwright & Co. | 03 Mar 2025 | 73.00 (78.92%) | Buy | 38.34 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 30 Apr 2025 | Announcement | Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025 |
| 27 Apr 2025 | Announcement | Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting |
| 01 Apr 2025 | Announcement | Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting |
| 31 Mar 2025 | Announcement | Revolution Medicines to Participate in April 2025 Investor Conferences |
| 26 Feb 2025 | Announcement | Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress |
| 24 Feb 2025 | Announcement | Revolution Medicines to Participate in March 2025 Investor Conferences |
| 19 Feb 2025 | Announcement | Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |